273 related articles for article (PubMed ID: 33210562)
21. Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.
Barr PM; Robak T; Owen C; Tedeschi A; Bairey O; Bartlett NL; Burger JA; Hillmen P; Coutre S; Devereux S; Grosicki S; McCarthy H; Li J; Simpson D; Offner F; Moreno C; Zhou C; Styles L; James D; Kipps TJ; Ghia P
Haematologica; 2018 Sep; 103(9):1502-1510. PubMed ID: 29880603
[TBL] [Abstract][Full Text] [Related]
22. Zanubrutinib for the treatment of chronic lymphocytic leukemia.
Bruzzese A; Martino EA; Labanca C; Mendicino F; Lucia E; Olivito V; Neri A; Morabito F; Vigna E; Gentile M
Expert Opin Pharmacother; 2023; 24(13):1409-1413. PubMed ID: 37350553
[No Abstract] [Full Text] [Related]
23. Ibrutinib-associated tumor lysis syndrome in chronic lymphocytic leukemia/small lymphocytic lymphoma and mantle cell lymphoma: A case series and review of the literature.
Titus-Rains KS; Brown JN; Hammond JM
J Oncol Pharm Pract; 2018 Oct; 24(7):544-549. PubMed ID: 28714377
[TBL] [Abstract][Full Text] [Related]
24. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.
Stephens DM; Byrd JC
Blood; 2019 Mar; 133(12):1298-1307. PubMed ID: 30642919
[TBL] [Abstract][Full Text] [Related]
25. Is HBV prophylaxis required during CLL treatment with ibrutinib?
Tedeschi A; Frustaci AM; Mazzucchelli M; Cairoli R; Montillo M
Leuk Lymphoma; 2017 Dec; 58(12):2966-2968. PubMed ID: 28535112
[No Abstract] [Full Text] [Related]
26. Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies-A single institution experience and a review of literature.
Shaikh H; Khattab A; Faisal MS; Chilkulwar A; Albrethsen M; Sadashiv S; Fazal S
J Oncol Pharm Pract; 2019 Jul; 25(5):1265-1270. PubMed ID: 30045682
[TBL] [Abstract][Full Text] [Related]
27. Pirtobrutinib in relapsed or refractory CLL and SLL.
Woyach JA
Clin Adv Hematol Oncol; 2024 Jun; 22(5):230-231. PubMed ID: 38805315
[No Abstract] [Full Text] [Related]
28. Cryptococcal infections in two patients receiving ibrutinib therapy for chronic lymphocytic leukemia.
Stankowicz M; Banaszynski M; Crawford R
J Oncol Pharm Pract; 2019 Apr; 25(3):710-714. PubMed ID: 29343153
[TBL] [Abstract][Full Text] [Related]
29. Zanubrutinib: a novel BTK inhibitor in chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Tam CS
Clin Adv Hematol Oncol; 2019 Jan; 17(1):32-34. PubMed ID: 30843894
[No Abstract] [Full Text] [Related]
30. Refractory pure red cell aplasia associated with chronic lymphocytic leukemia successfully treated with ibrutinib.
Goldschmidt N; Rund D
Leuk Lymphoma; 2017 Feb; 58(2):498-500. PubMed ID: 27756158
[No Abstract] [Full Text] [Related]
31. Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.
Kazianka L; Drucker C; Skrabs C; Thomas W; Melchardt T; Struve S; Bergmann M; Staber PB; Porpaczy E; Einberger C; Heinz M; Hauswirth A; Raderer M; Pabinger I; Thalhammer R; Egle A; Wendtner CM; Follows G; Hoermann G; Quehenberger P; Jilma B; Jaeger U
Leukemia; 2017 May; 31(5):1117-1122. PubMed ID: 27909342
[TBL] [Abstract][Full Text] [Related]
32. Rapid onset of hemophagocytic lymphohistiocytosis in a patient with refractory chronic lymphocytic leukemia treated with ibrutinib.
Poole A; Girard N; Clayton F; Tantravahi SK
Leuk Lymphoma; 2017 May; 58(5):1258-1261. PubMed ID: 27750463
[No Abstract] [Full Text] [Related]
33. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.
Davids MS; Brander DM; Kim HT; Tyekucheva S; Bsat J; Savell A; Hellman JM; Bazemore J; Francoeur K; Alencar A; Shune L; Omaira M; Jacobson CA; Armand P; Ng S; Crombie J; LaCasce AS; Arnason J; Hochberg EP; Takvorian RW; Abramson JS; Fisher DC; Brown JR;
Lancet Haematol; 2019 Aug; 6(8):e419-e428. PubMed ID: 31208944
[TBL] [Abstract][Full Text] [Related]
34. Severe ulcerative gastrointestinal toxicity following ibrutinib therapy: two case studies.
Pacoureau L; De Menthon M; Boytchev I; Lazure T; Rocher L; Lambotte O; Noël N
Leuk Lymphoma; 2021 Apr; 62(4):984-987. PubMed ID: 33179997
[No Abstract] [Full Text] [Related]
35. What should standard frontline therapy be in older patients with chronic lymphocytic leukemia? Ibrutinib should be standard frontline therapy.
Woyach JA
Clin Adv Hematol Oncol; 2016 May; 14(5):330-3. PubMed ID: 27379693
[No Abstract] [Full Text] [Related]
36. Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia.
İskender G; İskender D; Ertek M
Turk J Haematol; 2020 Aug; 37(3):208-209. PubMed ID: 32248674
[No Abstract] [Full Text] [Related]
37. Zanubrutinib more effective and better tolerated than ibrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma.
Nierengarten MB
Cancer; 2023 May; 129(10):1466. PubMed ID: 37088994
[No Abstract] [Full Text] [Related]
38. Ibrutinib for the treatment of chronic lymphocytic leukemia.
Deodato M; Frustaci AM; Zamprogna G; Cairoli R; Montillo M; Tedeschi A
Expert Rev Hematol; 2019 May; 12(5):273-284. PubMed ID: 30916599
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular Side Effects of Tyrosine Kinase Inhibitor Ibrutinib (Imbruvica) and Interaction With Direct Oral Anticoagulant.
Khalid M; Khattak F; Ramu V
Am J Ther; 2018; 25(6):e768-e769. PubMed ID: 29916856
[No Abstract] [Full Text] [Related]
40. Hair and Nail Changes During Long-term Therapy With Ibrutinib for Chronic Lymphocytic Leukemia.
Bitar C; Farooqui MZ; Valdez J; Saba NS; Soto S; Bray A; Marti G; Wiestner A; Cowen EW
JAMA Dermatol; 2016 Jun; 152(6):698-701. PubMed ID: 26982511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]